Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect Cyclacel Pharmaceuticals to post earnings of ($0.29) per share and revenue of $0.03 million for the quarter.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last announced its quarterly earnings results on Wednesday, April 2nd. The biotechnology company reported ($5.28) EPS for the quarter, missing analysts’ consensus estimates of ($4.64) by ($0.64). Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million.
Cyclacel Pharmaceuticals Price Performance
Shares of NASDAQ CYCC opened at $0.25 on Friday. Cyclacel Pharmaceuticals has a 1-year low of $0.17 and a 1-year high of $3.08. The business’s 50 day moving average is $4.32 and its two-hundred day moving average is $5.63. The stock has a market capitalization of $52.68 million, a P/E ratio of -0.03 and a beta of 0.52.
Cyclacel Pharmaceuticals Announces Dividend
The business also recently declared a dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 29th were given a $2.40 dividend. The ex-dividend date of this dividend was Tuesday, April 29th. Cyclacel Pharmaceuticals’s dividend payout ratio is presently -4.29%.
Insiders Place Their Bets
In other news, CEO David E. Lazar sold 12,164,301 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $0.48, for a total value of $5,838,864.48. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 68.00% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Separately, StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals in a research note on Saturday. They issued a “sell” rating on the stock.
Read Our Latest Stock Report on Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Further Reading
- Five stocks we like better than Cyclacel Pharmaceuticals
- Utilities Stocks Explained – How and Why to Invest in Utilities
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
- ETF Screener: Uses and Step-by-Step Guide
- Here’s The Reason Goldman Sachs Is Bullish On MercadoLibre Stock
- What Do S&P 500 Stocks Tell Investors About the Market?
- Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.